U.S. Study Alarmingly Finds That Young Males Are At A High Risk of Myocarditis From SARS-CoV-2 Infection. New Nutraceutical Product Might Help
A new observational study conducted in the United States by researchers from Case Western Reserve University-Ohio, Akron Children’s Hospital Heart Center-Ohio and the MetroHealth System-Cleveland has alarmingly revealed that the incidence rate of myocarditis due to the SARS-CoV-2 coronavirus infection is about 450 per million cases among young males. Young males with the COVID-19 disease, which is the disease that results from infection by SARS-CoV-2, are 6-times more susceptible to myocarditis than those who received the COVID-19 vaccine.
The shocking study findings were obtained via the meta-analysis of a data set that was created from the TriNetX Research Network, aggregating electronic health records from 48 mostly large U.S. Healthcare Organizations (HCOs). Inclusion criteria were a first COVID-19 diagnosis during the April 1, 2020 - March 31, 2021 time period, with an outpatient visit 1 month to 2 years before, and another 6 months to 2 years before that. Analysis was stratified by sex and age (12-17, 12-15, 16-19). Patients were excluded for any prior cardiovascular condition. Primary outcome was an encounter diagnosis of myocarditis within 90 days following the index date. Rates of COVID-19 cases and myocarditis not identified in the system were estimated and the results adjusted accordingly. Wilson score intervals were used for 95% confidence intervals due to the very low probability outcome.
for the 12-17-year-old male cohort, 6/6,846 (0.09%) patients developed myocarditis overall, with an adjusted rate per million of 876 cases (Wilson score interval 402 - 1,911). For the 12-15 and 16-19 male age groups, the adjusted rates per million were 601 (257 - 1,406) and 561 (240 - 1,313).
For 12-17-year-old females, there were 3 (0.04%) cases of myocarditis of 7,361 patients. The adjusted rate was 213 (73 - 627) per million cases. For the 12-15- and 16-19-year-old female cohorts the adjusted rates per million cases were 235 (64 - 857) and 708 (359 - 1,397). The outcomes occurred either within 5 days (40.0%) or from 19-82 days (60.0%).
The study findings were published on a preprint server and are currently being peer reviewed. https://www.medrxiv.org/content/10.1101/2021.07.23.21260998v1
To date, a growing amount of evidence has identified myocarditis as a rare side-effect of mRNA-based COVID-19 vaccines. The risk-benefit analysis of COVID-19 vaccines has indicated that young males under the age of 30 years are 10-times more susceptible to myocarditis as compared to those over the age of 30. The highest risk of myocarditis has been observed in males aged 12 to 17 years after receiving the 2nd vaccine dose.
However aside from vaccin
ations, SARS-CoV-2 infection has been found to increase the risk of myocarditis.
In hospitalized COVID-19 patients, myocarditis has been identified as a serious complication, even for those without a history of cardiovascular disease. However, there remains an insufficient amount of information available to assess the risk of myocarditis in low-risk COVID-19 patients.
The study team had estimated the prevalence of myocarditis in young male COVID-19 patients who are under the age of 20 years. The study was conducted on young males and females with confirmed COVID-19 diagnoses who did not have a history of any cardiovascular disease.
For the study, three specific age groups were considered which included individuals between 12 and 17 years of age, 12-15 years, and 16-19 years. The studied age groups corresponded to the previously identified high-risk myocarditis cohorts related to mRNA-based COVID-19 vaccination.
In order to include information about any missed COVID-19 cases, an adjusted number of COVID-19 cases were derived for each tested age group using the population-level infection rate and study-estimated COVID-19 prevalence.
Any incidence of myocarditis
that occurred within 90 days following COVID-19 diagnosis was considered for the analysis. Patients immunized with mRNA-based COVID-19 vaccines prior to a myocarditis diagnosis were excluded from the analysis.
Shockingly in the 12-17 years age group, about 0.09% of male COVID-19 patients were diagnosed with myocarditis. This corresponded to a rate of 876 myocarditis cases per million male COVID-19 patients. After adjusting for missed COVID-19 cases, an incidence rate of 450 myocarditis cases per million patients was estimated.
Also for the 12-15 and 16-19 age groups, the adjusted myocarditis cases per million patients were estimated to be 601 and 561, respectively.
However in female COVID-19 patients belonging to the age groups of 12-17 years, 12-15 years, and 16-19, the adjusted rates of myocarditis per million patients were estimated to be 213, 235, and 708, respectively.
Collectively by considering the entire study population, including males and females, the adjusted rates of myocarditis per million patients were estimated to be 328, 416, and 643 for the 12-17 years, 12-15 years, and 16-19 years age groups, respectively.
Interestingly of all identified myocarditis cases, about 40% occurred within 5 days and 60% occurred within 19 to 82 days following COVID-19 diagnosis.
From the study findings, it can be concluded that the prevalence of myocarditis in young male COVID-19 patients is 450 per million cases. Previous studies have estimated that the incidence rate of myocarditis following mRNA vaccination in the high-risk age group of 12-17 years is about 76 cases per million vaccine recipients.
The study highlights that young males with SARS-CoV-2 infection are 6-times more susceptible to develop myocarditis as compared to those who received mRNA-based COVID-19 vaccines.
In a separate development, there is a buzz going around the research community about a new nutraceutical compound that was developed by a German Biotech company based in Pune-India that was initially developed as an adjuvant to treat COVID-19.
The phytochemical based nutraceutical called Vedicinals9 has now been found to be able to not only treat COVID-19 but also help those inflicted with myocarditis or other heart related conditions to recuperate faster.
The Vedicinals9 nutraceutical suspension has shown in animal trials and human clinical trials to control the underlying factors leading to myocarditis.
The nutraceutical suspension not only lead to faster viral clearance which was the main underlying cause but also controlled inflammatory and thrombotic factors very efficiently, like IL-6, CRP and D-Dimer levels, as well as protecting the myocardial muscle tissues.
As the COVID-19 pandemic accelerates and becomes worse with more catastrophic surges, more safe therapeutic products are urgently needed to deal not just with the SARS-CoV-2 infection but also with the variety of chronic medical conditions the novel coronavirus brings along.
NOTE: All readers are advised to do their own due diligence. with regards to Vedicinals9. Thailand Medical News does not endorse nor promote this product as we have never had the opportunity to try nor test the product.Our write up is only based on study literature available.
For more on Myocarditis and SARS-CoV-2
, keep on logging to Thailand Medical News.